Fool.com
The World's Greatest Investing Community
Results 51 - 60 of 299 : Previous 2 3 4 5 6 7 8 9 10 Next
Can the European giant produce enough new drugs to offset a series of upcoming patent expirations?
Clinical Trial Positive, Stock Not So Much
Isis and Genzyme hit a homer, but they'll need another big play to win the game.
The Cherry on Pfizer's Acquisition Sundae
Pfizer may inherit a lawsuit.
Flip-Flopping: Not Just for Politicians Anymore
The FDA's change is good for companies.
Is There Life After 600% Returns?
Don't ignore companies just because they've been on a tear.
Pfizer's giving them away.
4-Star Stocks Poised to Pop: AstraZeneca
Market-trouncing returns could be written in these four stars.
This Is Your Dare-to-Be-Great Moment
Are you going to let it pass by?
Brilliant, Now Let's See the Data
AstraZeneca's drug beats a blockbuster, but the devil may be in the details.
Slimming down in anticipation of L-day.
Legal Information © 1995 - 2009 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK